Through the development of the Selection of Phage-displayed Accessible Recombinant Targeted Antibodies technology, novel recombinant antibodies against GRP78 have been identified, showing robust tumor localization, with demonstrated potential clinical utility for antibody-drug conjugates and gene therapy (114). Here, HSPA5 is linked to neoplasm.